Furthermore, the underlying therapeutic mechanisms of the combination are possibly associated with multiple molecules and pathways, with a particular emphasis on ESR1, CYP3A4, CYP2C19, CYP2C9, ALOX15, MAP2K2, CASP3, NFKB1, PIK3CA, and PIK3R1 targets, as well as chemical carcinogenesis-receptor activation and colorectal cancer pathways. Here, ALOX15 is linked to colorectal cancer.